NCT01957579 2017-06-12A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell MalignanciesAstraZenecaPhase 1 Completed32 enrolled 23 charts